AZD9574

PreclinicalSmall molecule

AstraZeneca

AZD9574 is one of 62 small molecule programs targeting Ovarian Cancer. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Ovarian CancerRecruiting

Advanced Solid MalignanciesRecruiting

Ovarian CancerPreclinical

Recruiting

Advanced Solid MalignanciesPreclinical

Recruiting

Competition

Competitive Landscape

209 competitors in Ovarian Cancer

#DrugCompanyPhaseTrials

Avastin

Roche

Phase 3

92 2

Pegylated Liposomal Doxorubicin

Merck & Co.

Phase 3

35 3

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

24 4

Adriamycin

Pfizer

Phase 3

8 5

Imfinzi

AstraZeneca

Phase 3

8 6

Opdivo

Bristol-Myers Squibb

Phase 3

8 7

Lynparza

RRisen (Suzhou) Pharma Tech Co., Ltd.

Phase 3

14 8

Herceptin

Roche

Phase 3

3 9

Afinitor

Novartis

Phase 3

2 10

Neulasta

Amgen

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

PreclinicalRecruiting

Advanced Solid Malignancies

NCT05417594

Q3 2028

PreclinicalRecruiting

Ovarian Cancer

NCT05797168

Q1 2029

PreclinicalRecruiting

Metastatic Prostate Cancer

NCT07181161

Q3 2029

PreclinicalRecruiting

Metastatic Prostate Cancer

NCT07590934

Clinical

Trials by Indication[1]

Metastatic Prostate Cancer2 trials

A Modular Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AZD0516 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Metastatic Prostate Cancer

Recruiting· AstraZeneca logo

AstraZeneca·Preclinical·NCT07181161·283 enrolled

A Phase Ib/II, Open-label, Multi-centre, Platform Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Multiple Anti-Cancer Agents in Metastatic Prostate Cancer

Recruiting· AstraZeneca logo

AstraZeneca·Preclinical·NCT07590934·152 enrolled

Ovarian Cancer1 trial

A Modular Phase I/IIa, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Ascending Doses of AZD5335 Monotherapy and in Combination With Anti-cancer Agents in Participants With Solid Tumors

Recruiting· AstraZeneca logo

AstraZeneca·Preclinical·NCT05797168·622 enrolled

Advanced Solid Malignancies1 trial

A Modular Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (CERTIS1)

Recruiting· AstraZeneca logo

AstraZeneca·Preclinical·NCT05417594·695 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for AZD9574. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AZD9574 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AZD9574. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: AstraZeneca

AZD9574

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Q3 2028

Q1 2029

Q3 2029

Trials by Indication[1]

Metastatic Prostate Cancer2 trials

Ovarian Cancer1 trial

Advanced Solid Malignancies1 trial

References

Drug Info

Quick Facts

Related News